← SynDRA
S-ruxolitinib
SynDRA canonical compound SYN0062918 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | JAK1 | JAK2 | JAK3 |
|---|
| Mechanism of action | JAK inhibitor |
|---|
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CYP1A2
- CYP2C19
- CYP2C9
- CYP2D6
- CYP3A4
- HDAC6
- HIF1A
- SMN1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- Incb 18424
- RefChem:1087263
- Ruxolitinib (S enantiomer)
- S-Ruxolitinib (INCB018424)
- (S)-Ruxolitinib
- C17H18N6
- ruxolitinib-(S)
- MFCD13184797
- Ruxolitinib, (S)-
- WVA83G6MCW
- SCHEMBL99225
- orb1301027
- SCHEMBL29808249
- EX-A4005
- RMB68537
- BDBM50557386
- HY-50856A
- s2902
- AKOS005145906
- CCG-265007
- AC-30902
- MS-24437
- DB-309925
- SW220207-1
- T6156
- F85017
- Ruxolitinib Impurity A (Ruxolitinib Enantiomer)
- BRD-K19601669-001-03-5
- (3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile
- Ruxolitinib phosphate, (S)-
- SG32XD66ML
- SCHEMBL31073616
- (S)-Ruxolitinib Phosphate
- T61988
- orb1688050
- (S)-Ruxolitinib (2S,3S)-dibenzoyltartrate
- QP89H9XWU9
Look up S-ruxolitinib in the interactive SynDRA portal →